Nephrol Dial Transplant (2002) 17: 191-195
© 2002 European Renal Association-European Dialysis and Transplant Association
Editorial Comments
The adipose tissue—a novel endocrine organ of interest to the nephrologist
cekDepartment of Nephrology, Endocrinology and Metabolic Diseases, Silesian University School of Medicine, Katowice, Poland
Keywords: adipose tissue; cardiovascular morbidity; obesity
Introduction
Obesity is a challenging health problem in Western societies. It is a risk factor for cardiovascular morbidity and mortality. Recent studies showed that adipose tissue is not only a passive energy store, but also an active endocrine organ, the secretions of which influence the function of many systems. It has been well known for decades that obesity influences the main ‘players’ of blood pressure regulation, in other words, the heart (increased cardiac output, cardiomyocyte hypertrophy), blood vessels (atherosclerotic changes, increased vascular resistance secondary to hypertrophy of vascular myocytes, increased vascular tone induced by sympathetic activity, abnormal paracrine/autocrine function of the endothelial cells), kidneys (sodium retention, activation of the renal renin-angiotensin system, development of obesity-related glomerulopathy), and the sympathetic nervous system (enhanced activity).
In addition, obesity leads to endocrine, metabolic, haemostatic and haematological abnormalities.
- • Endocrine: enhanced activity of the renin-angiotensin-system, hyperinsulinaemia with insulin resistance, diabetes mellitus type 2, hypercortisolaemia, resistance to
. . . [Full Text of this Article]
Adiponectin
Resistin
Tumour necrosis factor
Plasminogen activator inhibitor-1
The renin-angiotensin system
Conclusion
Notes
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Barraclough and C. K. Yeung Lipomatosis and focal segmental glomerulosclerosis: causation, association or coincidence? NDT Plus, February 1, 2008; 1(1): 55 - 55. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wiecek, M. Adamczak, and J. Chudek Adiponectin--an adipokine with unique metabolic properties Nephrol. Dial. Transplant., April 1, 2007; 22(4): 981 - 988. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kowalska, M. Straczkowski, A. Nikolajuk, A. Krukowska, I. Kinalska, and M. Gorska Plasma adiponectin concentration and tumor necrosis factor-{alpha} system activity in lean non-diabetic offspring of type 2 diabetic subjects Eur. J. Endocrinol., February 1, 2006; 154(2): 319 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Narkiewicz Obesity and hypertension--the issue is more complex than we thought Nephrol. Dial. Transplant., February 1, 2006; 21(2): 264 - 267. [Full Text] [PDF]
|
|
|
|
|
|
A. Wi""cek How does leptin contribute to uraemic cachexia? Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2620 - 2622. [Full Text] [PDF]
|
|
|
|
|
|
G. Wolf After all those fat years: renal consequences of obesity Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2471 - 2474. [Full Text] [PDF]
|
|